Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 10/20 | 0.74 |
| ▸ | NPC1 | O15118 | 10/20 | 0.74 |
| ▸ | RAB9A | P51151 | 9/20 | 0.74 |
| ▸ | MEN1 | O00255 | 8/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.74 |
| ▸ | THRB | P10828 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 10/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | RECQL | P46063 | 2/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | PHGDH | O43175 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15359676 | 1.00 | GAA (0.74) | GAANPC1RAB9AMEN1KMT2A | |
| SCHEMBL12717686 | 0.76 | GAA (0.61) | GAANPC1RAB9AMEN1KMT2A | |
| SCHEMBL12351248 | 0.75 | MAPT (1.00) | GAANPC1RAB9AMEN1KMT2A | |
| SCHEMBL7035502 | 0.74 | KDM4E (0.71) | GAANPC1RAB9AMEN1KMT2A | |
| SCHEMBL10280286 | 0.73 | MAPT (1.00) | GAANPC1RAB9AMEN1KMT2A | |
| SCHEMBL28373071 | 0.70 | KEAP1 (0.79) | GAANPC1RAB9AMEN1KMT2A | |
| SCHEMBL28373067 | 0.70 | KEAP1 (0.79) | GAANPC1RAB9AMEN1KMT2A | |
| SCHEMBL28369101 | 0.69 | KEAP1 (0.87) | GAANPC1MEN1KMT2AHPGD | |
| SCHEMBL28369102 | 0.69 | KEAP1 (0.87) | GAANPC1MEN1KMT2AHPGD | |
| SCHEMBL6419258 | 0.69 | PHGDH (0.57) | GAANPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440705-B2 | 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440705-B2 | 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2433634-A2 | Compounds, compositions and methods of inhibiting a-synuclein toxicity | The Whitehead Institute for Biomedical Research (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | SNCA, PARK7, HTT | GAA 62/4885NPC1 2064/4885RAB9A 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.